Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q96EK5
UPID:
KBP_HUMAN
Alternative names:
KIF1-binding protein; Kinesin family binding protein
Alternative UPACC:
Q96EK5; A8K5M8; Q9BR89; Q9ULE1; Q9Y428
Background:
KIF-binding protein, also known as KIF1-binding protein or Kinesin family binding protein, plays a crucial role in the organization of axonal microtubules. It is essential for axonal outgrowth and maintenance during the development of the peripheral and central nervous system.
Therapeutic significance:
Goldberg-Shprintzen syndrome, a disorder marked by intellectual disability, microcephaly, and dysmorphic facial features, often accompanied by Hirschsprung disease, is linked to variants affecting the KIF-binding protein gene. Understanding the role of KIF-binding protein could open doors to potential therapeutic strategies for this syndrome.